High-dose intravenous human immunoglobulin in polymyositis resistant to treatment

S. Jann, S. Beretta, M. Moggio, L. Adobbati, G. Pellegrini

Research output: Contribution to journalArticlepeer-review

Abstract

Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

Original languageEnglish
Pages (from-to)60-62
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume55
Issue number1
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Fingerprint Dive into the research topics of 'High-dose intravenous human immunoglobulin in polymyositis resistant to treatment'. Together they form a unique fingerprint.

Cite this